Invesco
STML

Invesco’s Stemline Therapeutics, Inc. STML Stock Holding History

Invesco’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,263
Closed -$196K – 3820
2019
Q1 		$196K Sell
15,263
-5,705
-27% -$64.5K ﹤0.01% 3626
2018
Q4 		$199K Sell
20,968
-115,643
-85% -$1.5M ﹤0.01% 3562
2018
Q3 		$2.27M Buy
136,611
+116,413
+576% +$1.87M ﹤0.01% 2674
2018
Q2 		$324K Sell
20,198
-59,295
-75% -$1.06M ﹤0.01% 3569
2018
Q1 		$1.22M Buy
+79,493
New +$1.24M ﹤0.01% 2937
2017
Q1 		– Sell
-169,058
Closed -$1.81M – 3783
2016
Q4 		$1.81M Buy
169,058
+46,636
+38% +$564K ﹤0.01% 2652
2016
Q3 		$1.33M Sell
122,422
-75
-0.1% -$610 ﹤0.01% 2799
2016
Q2 		$829K Sell
122,497
-3,730
-3% -$23.5K ﹤0.01% 3004
2016
Q1 		$588K Sell
126,227
-3,147
-2% -$15.4K ﹤0.01% 3183
2015
Q4 		$816K Sell
129,374
-3,847
-3% -$31.2K ﹤0.01% 3057
2015
Q3 		$1.18M Buy
133,221
+2,828
+2% +$29.7K ﹤0.01% 2829
2015
Q2 		$1.53M Sell
130,393
-1,812
-1% -$25.2K ﹤0.01% 2804
2015
Q1 		$1.91M Buy
132,205
+3,309
+3% +$50.6K ﹤0.01% 2631
2014
Q4 		$2.2M Buy
128,896
+50,745
+65% +$732K ﹤0.01% 2444
2014
Q3 		$974K Sell
78,151
-10,316
-12% -$127K ﹤0.01% 2985
2014
Q2 		$1.3M Buy
88,467
+8,471
+11% +$130K ﹤0.01% 2849
2014
Q1 		$1.63M Buy
79,996
+38,262
+92% +$928K ﹤0.01% 2725
2013
Q4 		$818K Buy
41,734
+7,016
+20% +$187K ﹤0.01% 3210
2013
Q3 		$1.57M Buy
+34,718
New +$1.13M ﹤0.01% 2715

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco's STML Position: Q2 2019 in Review

Invesco sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 15,263 shares — an estimated $196K sold.

Invesco first reported a position in STML in Q3 2013 and held it in 19 quarters. The position peaked at $2.27M in Q3 2018. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

  • Invesco reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Invesco sold 15,263 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $196K.
  • Invesco first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 19 quarters.
  • Invesco's Stemline Therapeutics, Inc. position peaked at $2.27M in Q3 2018.
  • 96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Invesco's 13F filing for Q2 2019, filed 14 Aug 2019.